FINWIRES · TerminalLIVE
FINWIRES

奧本海默稱,微軟將獲得 Azure、Bookings 和 M365 定價方面的支援。

By

-- 奧本海默週一在一份報告中指出,微軟(MSFT)預計在2026年下半年受益於Azure的強勁增長和預訂量、Microsoft 365價格上漲、更嚴格的成本控制以及近期人工智慧管理方面的調整。 奧本海默表示,Azure可能成為主要驅動力,其模型預測第三財季(以固定匯率計算)將成長約39.9%,高於預期,並可能提振股價。 微軟將於4月29日公佈第三財季業績。 這家投資公司表示,Microsoft 365的業績應保持穩定,這得益於客戶的深度使用、安全性、產品間的整合以及近期的價格上漲。該公司還補充說,隨著更多資料中心容量上線並支援更多與人工智慧相關的需求,預計2026年下半年的預訂量將有所改善。 奧本海默分析師指出,風險包括管理層對人工智慧能否產生良好回報的擔憂可能會抑制旨在加速成長的資本投資;資料中心容量的限制可能會減緩成長;以及M365客戶可能會尋求在微軟平台之外建立代理商。奧本海默重申了其「跑贏大盤」評級和515美元的目標價。該公司表示,鑑於Azure業務展現出成長潛力,且在股價年初至今下跌13%以及第一季業績令人失望之後,市場對該公司第三財季的預期較低,因此第三財季的盈利前景看起來不錯。

Price: $422.56, Change: $-2.04, Percent Change: -0.48%

Related Articles

Insider Trading

Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing

Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml

$LFST
Australia

Celestica Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set

Celestica (CLS) reported Q1 adjusted earnings late Monday of $2.16 per diluted share, up from $1.20 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended March 31 was $4.05 billion, up from $2.65 billion a year earlier.Analysts surveyed by FactSet expected $4.04 billion.For Q2, the company expects adjusted EPS of $2.14 to $2.34 on revenue of $4.15 billion to $4.45 billion. Analysts expect EPS of $2.13 on revenue of $4.17 billion.The company now expects 2026 adjusted EPS of $10.15 on revenue of $19 billion, revised from $8.75 and $17 billion, respectively, expected earlier. Analysts expect EPS of $8.93 on revenue of $17.34 billion.

$CLS
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.

$AMP